Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;158(3):705-731.e5.
doi: 10.1053/j.gastro.2019.12.001. Epub 2019 Dec 6.

AGA Technical Review on Gastric Intestinal Metaplasia-Natural History and Clinical Outcomes

Andrew J Gawron  1 , Shailja C Shah  2 , Osama Altayar  3 , Perica Davitkov  4 , Douglas Morgan  5 , Kevin Turner  6 , Reem A Mustafa  7
Affiliations

AGA Technical Review on Gastric Intestinal Metaplasia-Natural History and Clinical Outcomes

Andrew J Gawron et al. Gastroenterology. 2020 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Correa Cascade with histology
Figure 2:
Figure 2:
PRISMA flow diagram
Figure 3a:
Figure 3a:
Relative risk of all-cause mortality among patients with H. pylori infection after H. pylori treatment versus placebo (all patients, with or without GIM)
Figure 3b:
Figure 3b:
Relative risk of gastric cancer-related mortality among patients with H. pylori infection after H. pylori treatment versus placebo (all patients, with or without GIM)
Figure 4a:
Figure 4a:
Relative risk of incident gastric cancer among patients with H. pylori infection after H. pylori treatment versus placebo (all patients, with or without GIM)
Figure 4b:
Figure 4b:
Relative risk of incident gastric cancer among patients with H. pylori infection and confirmed GIM after H. pylori treatment versus placebo
Figure 5a:
Figure 5a:
Relative risk of progression to worse global histology from baseline among patients with H. pylori infection after H. pylori treatment versus placebo (all patients, with or without GIM)
Figure 5b:
Figure 5b:
Relative risk of progression to worse global histology from baseline among patients with H. pylori infection and confirmed GIM after H. pylori treatment versus placebo
Figure 6a:
Figure 6a:
Relative risk of regression to improved global histology from baseline among patients with H. pylori infection after H. pylori treatment versus placebo (all patients, with or without GIM)
Figure 6b:
Figure 6b:
Relative risk of regression to improved global histology from baseline among patients with H. pylori infection and confirmed GIM after H. pylori treatment versus placebo
Figure 7:
Figure 7:
Incidence rate per 10,000 person-years of any dysplasia in patients with GIM
Figure 8:
Figure 8:
Cumulative incidence of any dysplasia at 3-, 5-year, and 8-years in patients with GIM
Figure 9:
Figure 9:
Cumulative incidence of HGD or gastric cancer at 5-years in patients with GIM
Figure 10a:
Figure 10a:
Incidence rate of gastric cancer per 10,000 person-years in patients with GIM (all geographies)
Figure 10b:
Figure 10b:
Incidence rate of gastric cancer per 10,000 person-years in patients with GIM (US geography only)
Figure 11:
Figure 11:
Cumulative incidence of gastric cancer at 3-, 5-, and 10-years in patients with GIM
Figure 12:
Figure 12:
Cumulative incidence of gastric cancer in GIM patients according to race and ethnicity (4–7 years followup)
Figure 13:
Figure 13:
Relative risk of progression to gastric cancer in GIM patients with versus without a family history of gastric cancer
Figure 14a:
Figure 14a:
Relative risk of progression to gastric cancer according to incomplete versus complete GIM on baseline histology
Figure 14b:
Figure 14b:
Relative risk of progression to any dysplasia according to incomplete versus complete GIM on baseline histology
Figure 15:
Figure 15:
Relative risk of progression to gastric cancer according to topographic extent of GIM, extensive versus limited1
Figure 16:
Figure 16:
Relative risk of progression of GIM to gastric cancer according to tobacco smoker versus non-smoker status
Figure 17:
Figure 17:
Cumulative risk of regression to improved global histology at 1-year, 3-year, and 5-year follow up in patients with GIM
Figure 18:
Figure 18:
Cumulative incidence of gastric cancer at 1 year in patients with GIM
See this image and copyright information in PMC

Comment in

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;September 12. ep. - PubMed
    1. Anderson WF, Rabkin CS, Turner N, et al. The Changing Face of Noncardia Gastric Cancer Incidence Among US Non-Hispanic Whites. J. Natl. Cancer Inst 2018;110:608–615. - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA. Cancer J. Clin 2017;67:7–30. - PubMed
    1. Merchant SJ, Kim J, Choi AH, et al. A rising trend in the incidence of advanced gastric cancer in young Hispanic men. Gastric Cancer 2017;20:226–234. - PMC - PubMed
    1. Anderson WF, Rabkin CS, Turner N, et al. The Changing Face of Noncardia Gastric Cancer Incidence Among US Non-Hispanic Whites. JNCI J. Natl. Cancer Inst 2018;110:608–615. - PMC - PubMed

Publication types

MeSH terms